Moderna (MRNA) R&D Day Highlights COVID-19 Vaccine - Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $107.00 price target on Moderna (NASDAQ: MRNA) after attending the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE